Compare DexCom, Inc. (DXCM) vs Unilever plc (UL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Unilever plc — how do they compare? DexCom, Inc. trades at $84.38 (market cap $31.81B), while Unilever plc trades at $61.94 (market cap $132.07B). The key difference: Unilever plc is far larger — about 4.2× DexCom, Inc.'s market cap, and Unilever plc pays a 3.48% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Unilever plc for 112 Days on average.
| DXCM | UL | |
|---|---|---|
Market Cap | $31.81B | $132.07B |
Volume | 2,861,821 | 2,873,862 |
Sector | Health | Consumer Staples |
52-Week High | $92.34 | $74.59 |
52-Week Low | $54.84 | $55.05 |
Typical Hold Time | 62 Days | 112 Days |
Enterprise Value | $31.26B | $157.21B |
Dividend Yield | — | 3.48% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.41, showing modest daily gains of 1.22% amid a bearish technical outlook. The company demonstrates strong fundamental performance with consistent earnings beats, including Q2 2026 EPS of $0.70 exceeding expectations of $0.611. Revenue growth remains robust, climbing from $2.9B in 2022 to $4.7B in 2025, while net income margins improved to 17.93%. Recent news highlights expansion opportunities in Type 2 diabetes care and executive promotions.
Wall Street maintains a bullish stance with 81% buy ratings and a $95.07 consensus price target, representing 13% upside potential. Key risks include competitive pressures in CGM markets and reimbursement challenges. The company's strong cash flow generation and expanding market opportunity in diabetes technology support long-term growth prospects despite current technical weakness.
Unilever (UL) trades at $61.94, up 1.88% today, amid bearish technical signals and mixed earnings performance. The stock shows strong profitability with 18.32% net margins and 54.56% ROE, though recent quarters saw EPS misses. Cash flow turned negative in 2025 at -$2.08B due to increased investing activity. The company is restructuring its portfolio, including the planned $65B food business merger with McCormick, while facing regulatory scrutiny in the UK.
Outlook remains cautious with analyst consensus divided (24% Buy, 51% Hold) and technical indicators bearish. Investment appeal lies in emerging market exposure and dividend stability, but risks include integration challenges from the McCormick deal, competitive pressures, and inconsistent earnings delivery. Valuation at 21.32 P/E appears reasonable given margins but requires execution improvement.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Unilever plc
Unilever is a diversified personal product (42% of 2021 sales by value), home care (20%), and packaged food (38%) company. Its brands include Knorr soups and sauces, Hellmann's mayonnaise, Lipton teas, Axe and Dove skin products, and the TRESemme haircare brand. The firm has been acquisitive in recent years
Read more on UL →
